This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.
How Potent Are JNJ & Other COVID-19 Jabs Against Delta Variant?
by Kinjel Shah
All available vaccines are mostly more effective against the Delta variant after two doses, and less effective after the first dose.
The Zacks Analyst Blog Highlights: Verizon, SAP, PetroChina, Moderna and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, SAP, PetroChina, Moderna and General Motors
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $235.11, marking a +0.06% move from the previous day.
Top Research Reports for Verizon, SAP & PetroChina
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), SAP SE (SAP), and PetroChina (PTR).
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
Moderna (MRNA) COVID-19 Vaccine Effective Against Delta Variant
by Zacks Equity Research
Moderna's (MRNA) share price reaches all-time high, following authorization from the government of India for mRNA-1273 and encouraging neutralizing activity against several COVID-19 variants demonstrated in studies.
Company News for Jun 30, 2021
by Zacks Equity Research
Companies in the news are: EPAC, CERE, PLBY, MRNA
Markets Tepid Ahead of This Week's Jobs Numbers
by Mark Vickery
The ADP private-sector payrolls Wednesday morning are expected to yield 550K new filled job positions for June.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $219.94, moving -0.09% from the previous trading session.
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
by Zacks Equity Research
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
5 Hot Stocks That Pushed Nasdaq ETF to New Highs
by Sweta Killa
After the wild swings last month, the tech-heavy Nasdaq Composite Index has been gaining momentum lately and reached a new peak driven by tech rally.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?
by Zacks Equity Research
The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US
by Zacks Equity Research
Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $197.84 in the latest trading session, marking a -1.86% move from the prior day.
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.
AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA
by Zacks Equity Research
The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks
by Zacks Equity Research
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.
COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart
by Indrajit Bandyopadhyay
The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.
ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens
by Sweta Jaiswal, FRM
Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $217 in the latest trading session, marking a -0.2% move from the prior day.
The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna